{"nctId":"NCT00329030","briefTitle":"Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401)","startDateStruct":{"date":"2005-12"},"conditions":["Lymphoma, B-Cell","Lymphoma, Large-Cell, Immunoblastic","Lymphoma, Non-Hodgkin"],"count":224,"armGroups":[{"label":"Rituxan/BEAM","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Autologous transplantation using rituxan/BEAM"]},{"label":"Bexxar/BEAM","type":"EXPERIMENTAL","interventionNames":["Drug: Autologous transplantation using Bexxar/BEAM"]}],"interventions":[{"name":"Autologous transplantation using rituxan/BEAM","otherNames":["Rituximab"]},{"name":"Autologous transplantation using Bexxar/BEAM","otherNames":["Tositumomab and Iodine I 131 Tositumomab Bexxar"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of persistent or recurrent REAL classification diffuse large B-cell lymphoma, composite lymphoma with more than 50% diffuse large B-cell lymphoma, mediastinal B-cell lymphoma\n* Demonstration of CD20+ on at least one histologic specimen\n* 18-80 years old at time of first registration\n* Three or fewer prior regimens of chemotherapy over the entire course of their disease treatment (including one induction chemotherapy and no more than 2 salvage chemotherapies); monoclonal antibody therapy and involved field radiation therapy will not be counted as prior therapies\n* Disease status of primary induction failure, first relapse, or second complete remission; all patients must have chemosensitive disease as demonstrated by response to induction or salvage chemotherapy with at least a partial response (as defined in the protocol)\n* No more than a 20% bone marrow involvement\n* Patients with adequate organ function as measured by:\n* Cardiac: American Heart Association Class I: Patients with cardiac disease but without resulting limitation of physical activity; ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain; additionally, patients greater than 60 years of age must have a left ventricular ejection fraction at rest of at least 40% demonstrated by Multi-Gated Acquisition Scan (MUGA)\n* Hepatic: Bilirubin less than 2.0 mg/dL (except for isolated hyperbilirubinemia attributed to Gilbert syndrome) and alanine transaminase (ALT) and aspartate transaminase (AST) less than 3x the upper limit of normal\n* Renal: Creatinine less than 2.0 mg/dL or creatinine clearance (calculated creatinine clearance is permitted) more than 40 mL/min; no hydronephrosis on CT scan prior to mobilization\n* Pulmonary: Carbon Monoxide Diffusing Capacity (DLCO), Volume forcibly exhaled in one second (FEV1), forced vital capacity (FVC) at least 45% of predicted (corrected for hemoglobin)\n* Autologous graft with a minimum of at least 1.5 X 10\\^6 CD34+ cells/kg (target greater than 2.0 X 10\\^6 CD34+ cells/kg. Peripheral blood stem cells (PBSC) are preferred; however, if PBSC mobilization fails, cells can be obtained by institutional practices (in cases where bone marrow will be used for transplantation, the required CD34+ dose does not apply and institutional practice for total nucleated cell dose should be used).\n* Initiate conditioning therapy within 3 months of mobilization\n* Signed informed consent\n\nExclusion Criteria:\n\n* Karnofsky performance score less than 70%\n* Transformed follicular lymphoma\n* Uncontrolled bacterial, viral, or fungal infection (currently taking medication and with progression or no clinical improvement)\n* Prior malignancies except resected basal cell carcinoma or treated cervical carcinoma in situ; cancer treated with curative intent less than 5 years previously will not be allowed unless approved by the Medical Monitor or Protocol Chair; cancer treated with curative intent less than 5 years previously will be allowed\n* Pregnant (positive β-HCG) or breastfeeding; this patient population is excluded due to the lack of data on the use of Bexxar in patients who are pregnant or breastfeeding\n* Seropositivity for HIV; this patient population is excluded due to the lack of data on the use of Bexxar in HIV positive patients and because the treatment regimens are too immunosuppressive for this patient population\n* Fertile men or women unwilling to use contraceptive techniques from the time of initiation of mobilization until six-months post-transplant\n* Prior autologous or allogeneic hematopoietic stem cell transplantation (HSCT)\n* Patients with evidence of myelodysplastic syndrome/acute myeloid leukemia (MDS/AML) or abnormal cytogenetic analysis indicative of MDS on the pre-transplant bone marrow examination\n* Patients with a prior severe reaction to Rituxan or Filgrastim (G-CSF). Patients with severe reactions to G-CSF that receive pre-medication for control of the reaction are not excluded from study.\n* Patients who have received prior radioimmunotherapy\n* Patients with known hypersensitivity to murine proteins","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Progression-free Survival (PFS)","description":"Patients are considered a failure for this endpoint if they die, relapse/progress, or receive anti-lymphoma therapy, other than post-transplant consolidative localized radiation (maximum 3 sites) to sites of prior bulk disease pre-transplant (\\> 3cm). The time to this event is the time from randomization until death, relapse/progression, receipt of anti-lymphoma therapy, or last follow up, whichever comes first.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.2","spread":null},{"groupId":"OG001","value":"56.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.6","spread":null},{"groupId":"OG001","value":"49.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"The event is death from any cause. The time to this event is the time from randomization to death or last follow-up. Surviving patients are censored at the time of last observation","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":null},{"groupId":"OG001","value":"73.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"60.1","spread":null},{"groupId":"OG001","value":"66.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Relapse/Progression","description":"The time to this event is measured from randomization. Deaths without relapse/progression are considered as a competing risk. Surviving patients with no history of relapse/progression are censored at time of last follow-up.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39.6","spread":null},{"groupId":"OG001","value":"40.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.2","spread":null},{"groupId":"OG001","value":"47.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Response (CR) and Partial Response (PR) Proportion","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.9","spread":null},{"groupId":"OG001","value":"71.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.5","spread":null},{"groupId":"OG001","value":"43.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Platelet Recovery to 20,000 Cells/μL","description":null,"paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.5","spread":null},{"groupId":"OG001","value":"82.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"84.5","spread":null},{"groupId":"OG001","value":"83.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Hematologic Function","description":"Hematologic function will be defined as ANC \\> 1,500 neutrophils/μL, hemoglobin \\> 10 g/dL without transfusion support, and platelet count \\> 100,000/μL without transfusion support.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.8","spread":null},{"groupId":"OG001","value":"38.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.0","spread":null},{"groupId":"OG001","value":"58.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Infection","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Mucositis Severity","description":"Mucositis severity will be scored per the modified Oral Mucositis Assessment Scale (OMAS) scoring system on a scale of 0 - 4, where 0 equals normal mucosa and 4 equals severe mucosa.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.72","spread":null},{"groupId":"OG001","value":"0.31","spread":null}]}]}]},{"type":"SECONDARY","title":"Immune Reconstitution","description":"Tests to be performed on peripheral blood include CD2, CD3, CD4, CD8, CD19, CD3+/CD25+, CD45 RA/RO, CD56+/CD3-.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1006.0","spread":"767.6"},{"groupId":"OG001","value":"1024.9","spread":"1074.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"921.8","spread":"694.8"},{"groupId":"OG001","value":"990.3","spread":"1056.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"342.8","spread":"223.9"},{"groupId":"OG001","value":"286.1","spread":"213.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"558.5","spread":"517.9"},{"groupId":"OG001","value":"697.7","spread":"901.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.4","spread":"140.5"},{"groupId":"OG001","value":"140.8","spread":"203.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.2","spread":"92.8"},{"groupId":"OG001","value":"118.0","spread":"127.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"469.3","spread":"404.4"},{"groupId":"OG001","value":"579.8","spread":"620.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"476.2","spread":"337.4"},{"groupId":"OG001","value":"727.8","spread":"798.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"125.1","spread":"94.6"},{"groupId":"OG001","value":"130.5","spread":"135.7"}]}]}]},{"type":"SECONDARY","title":"Immune Reconstitution of Quantitative Immunoglobulins","description":"Tests to be performed on peripheral blood for quantitative immunoglobulins include IgM, IgG and IgA.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68.5","spread":"42.6"},{"groupId":"OG001","value":"85.0","spread":"71.8"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"619.6","spread":"289.2"},{"groupId":"OG001","value":"643.8","spread":"395.3"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":"36.0"},{"groupId":"OG001","value":"79.0","spread":"154.4"}]}]}]},{"type":"SECONDARY","title":"Treatment-related Mortality (TRM)","description":"TRM is defined as death occurring in a patient from causes other than relapse or progression","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"2.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"3.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Neutrophil Recovery","description":"Time to neutrophil recovery will be the first of two consecutive days of \\> 500 neutrophils/μL following the expected nadir.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"93.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.1","spread":null},{"groupId":"OG001","value":"95.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":111},"commonTop":[]}}}